Shree Ganesh Remedies
- Market cap
- ₹ 804 Cr.
- P/E
- 54.7x
- P/B
- 5.16x
- 52-week range
- 477.05 – 749.85
- ROE
- 12%
- ROCE
- 15%
- Dividend yield
- 0%
- Debt / equity
- 0.19
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Shree Ganesh Remedies Limited is an India-based company, which is engaged in the business of bulk drug intermediates. The Company's products include intermediates by active pharmaceutical ingredient (API), and fine and specialty chemicals. Its human health API intermediates include antipsychotic, antidepression, oncology, diabetic, and diuretic. Its specialty & fine chemicals include aroma & health industry, agro-industry, polymer industry, and electronics industry. Its veterinary API intermediates include feed additives, antiparasitic, and anti-inflammatory. Its anti-arrhythmic API intermediates include amiodarone intermediates, dronedarone intermediates, and mesalazine intermediates. Its anti-cancer API intermediates include cabozantinib intermediates, gefitinib intermediates, olaparib intermediates, and raloxifene intermediates. Its anti-parasitic API intermediates include flubendazole intermediates, nitazoxanide intermediates, and praziquantel intermediates.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Shree Ganesh Remedies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)54.7 against a typical 34.3: pricier than most peers (1st = cheapest).164th of 220
- Sales growth−41.8% against a typical +15.6% from a year earlier.184th of 197
- Profit growth−67.5% against a typical +18.9% from a year earlier.141st of 160
- Size₹ 803.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).92nd of 199
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 28 | 37 | 25 | 32 | 27 | 24 | 25 | 30 | 21 | 33 | 14 |
| Expenses | 24 | 20 | 20 | 17 | 21 | 17 | 15 | 17 | 21 | 14 | 22 | 11 |
| Operating Profit | 9 | 8 | 17 | 8 | 11 | 10 | 10 | 7 | 10 | 7 | 11 | 3 |
| OPM % | 27.6% | 29.4% | 45.4% | 32.8% | 35% | 36.6% | 40.4% | 29.6% | 31.7% | 31.9% | 34.3% | 23.3% |
| Other Income | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 2 |
| Profit before tax | 9 | 7 | 16 | 6 | 9 | 8 | 9 | 5 | 7 | 4 | 9 | 2 |
| Tax % | 23.8% | 35.3% | 22.5% | 26.7% | 25.8% | 27.9% | 24.8% | 25% | 26.2% | 22.4% | 28.1% | 27.5% |
| Net Profit | 7 | 5 | 13 | 5 | 6 | 5 | 7 | 3 | 5 | 3 | 6 | 1 |
| EPS in Rs | 5.12 | 3.75 | 9.84 | 3.62 | 5 | 4.23 | 5.14 | 2.69 | 3.86 | 2.41 | 4.88 | 0.87 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 22%
- 5 Years
- 17%
- 3 Years
- 6%
- TTM
- −9%
- 10 Years
- 32%
- 5 Years
- 13%
- 3 Years
- 5%
- TTM
- −29%
- 10 Years
- —
- 5 Years
- 12%
- 3 Years
- 6%
- TTM
- —
- 10 Years
- 19%
- 5 Years
- 19%
- 3 Years
- 17%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Shree Ganesh Remedies | ₹ 652.15 | ₹ 804 Cr. | 54.7x | 5.2x | 12% | — |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 81.5x | 12.8x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 78.2x | 20.7x | — | 13.7% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 28.6x | 3.5x | — | 11.9% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 20.9x | 4.2x | 19.7% | 18.5% |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 39.6x | 5.7x | — | 19.8% |
Management
- Chandulal Manubhai Kothia
- Chairman of the Board, Managing Director
- Parth Chandulal Kothia
- Chief Financial Officer, Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.